Announcement on Changes to the Use of H Share Raised Funds

Securities Code: 002399 Securities Abbreviation: Hepalink Announcement No.: 2026-008 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announcement on Changes to the Use of H Share Raised Funds The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false representations, misleading statements, or material omissions. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") held the 20th meeting of the Sixth Board of Directors on March 30, 2026, and deliberated and passed the "Proposal on Changes to the Use of H Share Raised Funds." In accordance with the Company's long-term strategic plan, to improve the efficiency of the use of H share raised funds, and considering the Company's capital needs, the Company proposes to change the original intended use of H share raised funds. This matter is subject to the approval of the Company's 2025 Annual General Meeting of Shareholders. The specific details are hereby announced as follows: I. Basic Situation of Changes to the Use of H Share Raised Funds The original allocation, revised allocation, amount of net proceeds used as of the date of this announcement, and the amount of unused net proceeds from H share raised funds are detailed in the following table: Unit: RMB million | No. | Project Name | Raised Funds Total Investment | Net Proceeds from Raised Funds Used |